SomatoKine. Insmed.

Abstract

SomatoKine, a recombinant fusion of insulin-like growth factor-1 and its binding protein, BP-3, is being developed by Insmed (formerly Celtrix Pharmaceuticals) for the potential treatment of growth hormone insensitivity syndrome (GHIS), and as a potential injectable insulin sensitizer for the management of type 1 and type 2 diabetes in patients who are less sensitive to insulin therapy. By July 2002, the FDA had granted SomatoKine Orphan Drug status for the treatment of GHIS. Also at this time, a phase II trial in children suffering from GHIS was initiated. In September 2002, Insmed expected to initiate a further clinical trial in GHIS in early 2003, and planned to continue phase II development in type 1 and type 2 diabetes.

• Authors: Peter Norman
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 4 Issue 4 Pg. 466-71 (Apr 2003) ISSN: 1472-4472 [Print] England
• PMID: 12808889 (Publication Type: Journal Article, Review)

Chemical References

• Hypoglycemic Agents
• Recombinant Fusion Proteins
• somatoKine

Topics

• Animals
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Diabetes Mellitus (drug therapy)
• Humans
• Hypoglycemic Agents (adverse effects, chemical synthesis, metabolism, pharmacology, therapeutic use, toxicity)
• Recombinant Fusion Proteins (chemical synthesis, metabolism, pharmacology, therapeutic use)
• Structure-Activity Relationship